Researchers at Institute for Biotechnology Report New Data on Proinsulin [Solid lipid nanoparticles for hydrophilic biotech drugs: Optimization and cell viability studies (Caco-2 & HEPG-2 cell lines)]
By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Peptide Proteins. According to news reporting from Vila Real, Portugal, by NewsRx journalists, research stated, "Insulin was used as model protein to developed innovative Solid Lipid Nanoparticles (SLNs) for the delivery of hydrophilic biotech drugs, with potential use in medicinal chemistry. SLNs were prepared by double emulsion with the purpose of promoting stability and enhancing the protein bioavailability."
The news correspondents obtained a quote from the research from Institute for Biotechnology, "Softisan ® 100 was selected as solid lipid matrix. The surfactants (Tween ® 80, Span ® 80 and Lipoid ® S75) and insulin were chosen applying a 2(2) factorial design with triplicate of central point, evaluating the influence of dependents variables as polydispersity index (PI), mean particle size (z-AVE), zeta potential (ZP) and encapsulation efficiency (EE) by factorial design using the ANOVA test. Therefore, thermodynamic stability, polymorphism and matrix crystallinity were checked by Differential Scanning Calorimetry (DSC) and Wide Angle X-ray Diffraction (WAXD), whereas the effect of toxicity of SLNs was check in HepG2 and Caco-2 cells. Results showed a mean particle size (z-AVE) width between 294.6 nm and 627.0 nm, a PI in the range of 0.425-0.750, ZP about -3 mV, and the EE between 38.39% and 81.20%. After tempering the bulk lipid (mimicking the end process of production), the lipid showed amorphous characteristics, with a melting point of ca. 30 degrees C. The toxicity of SLNs was evaluated in two distinct cell lines (HEPG-2 and Caco-2), showing to be dependent on the concentration of particles in HEPG-2 cells, while no toxicity in was reported in Caco-2 cells. SLNs were stable for 24 h in in vitro human serum albumin (HSA) solution."
According to the news reporters, the research concluded: "The resulting SLNs fabricated by double emulsion may provide a promising approach for administration of protein therapeutics and antigens."
For more information on this research see: Solid lipid nanoparticles for hydrophilic biotech drugs: Optimization and cell viability studies (Caco-2 & HEPG-2 cell lines). European Journal of Medicinal Chemistry, 2014;81():28-34. European Journal of Medicinal Chemistry can be contacted at: Elsevier France-Editions Scientifiques Medicales Elsevier, 23 Rue Linois, 75724 Paris, France. (Elsevier - www.elsevier.com; European Journal of Medicinal Chemistry - www.elsevier.com/wps/product/cws_home/505813)
Our news journalists report that additional information may be obtained by contacting P. Severino, Univ Trasos OS Montes & Alto Douro CGB UTAD IBB, Center Genom & Biotechnol, Inst Biotechnol & Bioengn, P-5001801 Vila Real, Portugal. Additional authors for this research include T. Andreani, A. Jager, M.V. Chaud, M.H.A. Santana, A.M. Silva and E.B. Souto (see also Peptide Proteins).
Keywords for this news article include: Europe, Portugal, Vila Real, Proinsulin, Nanoparticle, Nanotechnology, Peptide Hormones, Peptide Proteins, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC